Detail akcie Unicycive Therap Rg online

Business Summary: Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Unicycive Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 27% to $11.9M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 2% to $22.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.76 to -$0.81.